Decoy Therapeutics Inc.

Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company focused on developing peptide conjugate therapeutics. The company utilizes its proprietary IMP 3 ACT™ platform, which incorporates machine learning ("ML") and artificial intelligence ("AI") tools with high-speed synthesis techniques. This platform is designed to engineer, optimize, and manufacture peptide conjugates to address unmet medical needs. Decoy Therapeutics aims to build a portfolio of these therapeutics, initially concentrating on infectious diseases and oncology. The company's goal is to become a fully integrated biopharmaceutical company in this field. Decoy Therapeutics has no products approved for commercial sales and has not generated any revenue from product sales. Prior to January 8, 2026, the company was known as Salarius Pharmaceuticals, Inc. ("Salarius"). In November 2025, Salarius completed a merger with Legacy Decoy and raised capital through financings. On January 8, 2026, Salarius changed its name to Decoy Therapeutics Inc.